Research Solutions Announces Agreement With Fortune 500 Biopharma Company Valued at $1 Million
An existing Article Galaxy customer is expanding its relationship through an enterprise-wide Scite agreement.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Research Solutions (NASDAQ: RSSS) announced an enterprise Scite agreement valued at $1 million with a Fortune 500 biopharmaceutical company.
The agreement expands the customer's longstanding Article Galaxy relationship to cover Scite deployment across all its research groups, including full API access and additional Scite datasets. It followed a months-long evaluation involving a technical trial and reviews across procurement, legal, security, architecture and AI governance, culminating in executive approval. Research Solutions describes the agreement as its largest to date and says it reflects demand across its pipeline for scientific literature access.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point$1 million Scite agreement with a Fortune 500 biopharmaceutical company expands an existing customer relationship. 1.6% of market cap
- Minor point. Forward-looking: it has not happened yet and may not happen.Enterprise rollout covers all customer research groups, full Scite API access and additional datasets.
Negative
- None.
Key Figures
- Agreement value
- $1 million
- Enterprise Scite agreement; described as the largest deal in company history
Key Terms
saas technical
mechanism-of-action medical
pharmacovigilance medical
api technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Largest Deal in Company History Further Supports Accelerating Enterprise Demand for AI Access to Scientific Literature
Built For How Large Pharma Deploys AI
Large R&D organizations are building new systems for evidence-based literature search, mechanism-of-action research, patent landscaping, and pharmacovigilance. Those systems are only as reliable as the sources they can read and cite. General-purpose models have limited coverage of scholarly content, can hallucinate citations, and cannot tell a supported finding from a contested one. Scite addresses each of these at the infrastructure level.
"Every large R&D organization we talk to is rebuilding their search and discovery tools, and every one of them has the same problem: their AI agents need trusted access to the scientific literature," said Roy W. Olivier, President and Chief Executive Officer of Research Solutions. "This agreement is the largest in our history, and it is not a one-off. It reflects demand we are seeing across our pipeline from companies that need to ground their systems in real evidence."
The agreement followed a months-long enterprise evaluation, which included live demonstrations, a technical trial, and reviews by procurement, legal, information security, technical architecture, and the customer's AI governance function, culminating in executive approval. The agreement covers an enterprise rollout of the Scite platform and full Scite API access with additional Scite datasets. These products allow the organization's internal tools to search and evaluate peer-reviewed literature, cite the evidence behind an answer, check the veracity of claims, and retrieve licensed full text through existing entitlements within the workflows the organization already runs.
About Research Solutions
Research Solutions, Inc. (NASDAQ: RSSS) is a holding Company providing software and AI solutions for enterprise R&D teams and academic institutions. Through its Scite and Article Galaxy products, the Company combines proprietary data, integrated workflows, and access infrastructure to give modern researchers and their AI systems the tools to find, trust, and act on scientific research faster.
For more information about Research Solutions, visit: www.researchsolutions.com | LinkedIn | Facebook | X
About Scite
Scite is an AI-powered research platform that helps researchers discover and evaluate scientific literature using Smart Citations - a technology that analyzes the full text of citing articles to show whether findings have been supported, mentioned, or contrasted by subsequent research. Scite is used by millions of researchers and is available as a web platform, browser extension, and Zotero plugin. For more information, visit https://www.scite.ai. Scite is a product of Research Solutions (NASDAQ: RSSS).
About Article Galaxy
Article Galaxy is a scientific literature access platform that gives R&D teams and academic institutions on-demand access to 80M+ full-text, peer-reviewed journal articles. Article Galaxy routes every request through the most cost-effective, compliant path, whether via an existing subscription, open access, or a one-time purchase, with article-level reuse rights built into each transaction. Researchers can order full text directly from PubMed, Google Scholar, and 70+ other discovery environments. For more information, visit https://www.articlegalaxy.com/. Article Galaxy is a product of Research Solutions (NASDAQ: RSSS).
Important Cautions Regarding Forward-Looking Statements
Certain statements in this press release may contain "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects," "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to several risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in the Company's most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Examples of forward-looking statements in this release include statements regarding customer demand, the Company's pipeline, and the expected adoption of its AI products. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to the Company's filings with the Securities and Exchange Commission.
View original content to download multimedia:https://www.prnewswire.com/news-releases/research-solutions-announces-agreement-with-fortune-500-biopharma-company-valued-at-1-million-302935837.html
SOURCE Research Solutions, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.